S everal autoimmune and infectious diseases are associated with immune-complex glomerulonephritis (ICGN). Simplistically, ICGN can be thought of as having three components: (i) an initiating adaptive immune response to an endogenous or exogenous antigen, (ii) the deposition or formation of immune-complexes within glomeruli, and (iii) inflammatory injury of the glomeruli (Figure 1 ). When the antigen is exogenous -such as in Hepatitis C-associated glomerulonephritis -the ideal approach is to eliminate the antigen. In cases where the antigen cannot be eliminated, however, most current therapies target the immune response to the antigen or the downstream mediators of injury. The complement cascade is group of plasma proteins that are activated by immune-complexes, and there has been a longstanding interest blocking complement activation as a treatment for ICGN 1,2 . Activation of the complement cascades causes glomerular injury through the generation of biologically active protein fragments, including C3a, C3b, C5a, and C5b-9. C5b-9 (the membrane attack complex) forms pores in the membranes of target cells and can cause lysis of the cells, whereas C3a, C5a, and tissuebound C3 activation fragments (C3b, iC3b, C3d) act through specific receptors. C5a is released as a soluble molecule and has two known receptors, the C5a receptor (C5aR1, CD88) and C5a-receptor-like 2 (C5L2) . In developing this model, the authors previously showed that mice deficient in the complement regulatory protein factor H (fH 2/2 mice) are susceptible to ICGN, whereas wild-type mice are resistant to injury in the model. Using mice with targeted deletion of C5aR1 the authors have also previously shown that C5a is an important mediator of glomerular injury in this model 8 . The current study expands on this work by treating mice with a pharmacologic antagonist of C5aR1 or with a CPN inhibitor. Treatment with the C5aR1 antagonist almost completely prevented glomerular injury in fH 2/2 mice. Conversely, inhibiting CPN made the glomerular disease worse. Considered along with the authors' previous studies, these results indicate that factor H is critical for preventing glomerular injury in this model. In the absence of factor H, endogenous CPN attenuates (but does not prevent) glomerular injury. Pharmacologic C5aR antagonism provides further protection from injury suggesting that most of the complement-induced injury is mediated by C5a.
An interesting finding of the earlier study was that mice lacking the C5a receptor developed lower titers of anti-apoferritin IgG and had reduced glomerular deposits of IgG 8 . Although complement activation may occur downstream of immune-complex deposition within the glomerulus, C5a signaling seems to contribute to the adaptive immune response to the apoferritin (the antigen in this model). In the current study the authors report that use of the C5aR1 antagonist also reduced the titer of anti-apoferritin IgG and glomerular IgG deposits, even though administration of the C5aR1 antagonist was started two weeks after disease induction with the apoferritin had begun. Thus, not only is signaling through C5aR1 important for the immune response against apoferritin, but continued signaling though the receptor is necessary to maintain the immune response. One cannot tell from these results whether the C5a signaling is occurring in the glomerulus or whether it happens elsewhere (such as in the spleen or lymph nodes).
What are the implications of this study? Most importantly, these results indicate that there may be a clinical benefit from C5a antagonism after the onset of disease. Ideally one would treat a disease as early as possible, but unfortunately glomerulonephritis is usually diagnosed only after overt signs and symptoms of disease have developed. The beneficial effect of C5aR1 antagonism on the immune response, even in established disease, is particularly interesting. Furthermore, the effects of C5aR1 antagonism are probably not antigen specific, and this therapeutic strategy may be beneficial in a wide range of autoimmune diseases. Clinical trials of a C5a receptor antagonist (CCX168) in patients with ANCA-associated vasculitis are currently ongoing (Clinical trial identifier NCT02222155 and NCT013 63388). This trial may provide crucial proof-of-concept evidence for the use of C5a receptor antagonists in human patients. Based on the results of Alexander and colleagues' work, it would also be useful to test C5a receptor blockade in a disease associated with ICGN. In addition to testing whether the treatment ameliorated disease, the effect of the treatment on levels of circulating autoantibodies and glomerular immune-complexes could also be examined. Figure 1 Model of the protective roles for factor H and carboxypeptidase N in immune-complex glomerulonephritis. Phase 1. Antibodies against an endogenous or exogenous antigen are formed. This can be due to the loss of tolerance to an endogenous protein, the persistence of an infectionassociated antigen, or the generation of neo-epitopes in injured or cancerous tissues. Phase 2. The immune-complexes deposit in glomeruli, where they engage pro-inflammatory pathways such as the complement system. Factor H limits complement activation by the immune-complexes. Phase 3. Pathologic factors are generated and cause glomerular injury. Carboxypeptidase N limits the pathologic effects of C5a. These same inflammatory factors feedback and help perpetuate the adaptive immune response. Factor H and carboxypeptidase N block this positive feedback, thereby attenuating the ongoing adaptive immune response to the antigen.
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